Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

• Status: Terminated
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US). Subjects will receive weekly injections of bapineuzumab for 3 years (156 doses). One dosage level will be included: 5 mg/week. All subjects will receive active treatment (bapineuzumab) and no subjects will receive placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborator: JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Criteria

Inclusion Criteria:

• Diagnosis of probable Alzheimer disease

• Completed preceding double-blind study (3133L1-2203 US)

• MMSE score > 9.

Exclusion Criteria:

• Significant brain MRI abnormalities

• Clinically important psychiatric symptoms

• History of stroke